COMPANY NAME: Memphis for Pharmaceutical & Chemical Industries. TRADE NAME: Neostigmine Tablets GENERIC NAME: Neostigmine bromide COMPOSITION: Active ingredient: Neostigmine bromide 15mg : Excipients Lactose monohydrate, Maize starch, Talc, Magnesium stearate. PHARMACEUTICAL FORM: Tablet. PHARMACOLOGICAL ACTION: PHARMACODYNAMICS: Neostigmine Bromide is an antagonist to cholinesterase, the enzyme which normally destroys acetylcholine. The action of Neostigmine Bromide can briefly be described, therefore, as the potentiation of naturally occurring acetylcholine. PHARMACOKINETICS: Neostigmine Bromide is a quaternary ammonium compound and is poorly absorbed from the gastro-intestinal tract. Following parenteral administration as the methylsulphate, neostigmine is rapidly eliminated with a plasma halflife of 50-90 minutes and is excreted in the urine both as unchanged drug and metabolites. It is metabolised partly by hydrolysis of the ester linkage. INDICATIONS: Myasthenia gravis, paralytic ileus; post-operative urinary retention. DOSAGE AND ADMINISTRATION: Neostigmine bromide has a slower onset of effect when given orally than when given parenterally, but the duration of action is longer and the intensity of action more uniform. To facilitate change of treatment from one route of administration to another, the following doses are approximately equivalent in effect:
